Avalo Therapeutics, Inc. short interest in 2026
In 2026, Avalo Therapeutics, Inc.'s disclosed short interest ran from 16.43% of shares outstanding on 15 Jan 2026 to 24.10% on 15 Sep 2026, a change of +7.67 percentage points. The year's high was 25.16% on 30 Apr 2026 and its low 11.90% on 15 May 2026, averaging 20.65% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 20.23 days on 14 Aug 2026. Full history: Avalo Therapeutics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 16.43% (15 Jan 2026)
- End of year
- 24.10% (15 Sep 2026)
- Change
- +7.67 pp
- High
- 25.16% (30 Apr 2026)
- Low
- 11.90% (15 May 2026)
- Average
- 20.65%
- Highest days to cover
- 20.23 (14 Aug 2026)
- SEC filings marked
- 8
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 16.43% | 10.17 | results (8-K) |
| 30 Jan 2026 | 17.56% | 8.13 | |
| 13 Feb 2026 | 19.84% | 9.44 | |
| 27 Feb 2026 | 20.30% | 7.21 | |
| 13 Mar 2026 | 22.55% | 5.83 | |
| 31 Mar 2026 | 24.32% | 6.21 | 10-K filed, results (8-K) |
| 15 Apr 2026 | 22.98% | 6.12 | |
| 30 Apr 2026 | 25.16% | 8.10 | |
| 15 May 2026 | 11.90% | 1.59 | results (8-K), 10-Q filed, results (8-K) |
| 29 May 2026 | 12.14% | 4.36 | |
| 15 Jun 2026 | 14.10% | 5.53 | |
| 30 Jun 2026 | 23.41% | 4.26 | |
| 15 Jul 2026 | 24.12% | 10.68 | |
| 31 Jul 2026 | 24.64% | 14.38 | |
| 14 Aug 2026 | 24.41% | 20.23 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 23.10% | 15.17 | |
| 15 Sep 2026 | 24.10% | 13.24 |
See also: Avalo Therapeutics, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.